ANCN - Anchiano Therapeutics EPS misses by $0.25 November, 15 2019 08:47 AM Chemomab Therapeutics Anchiano Therapeutics (NASDAQ:ANCN): Q3 GAAP EPS of -$0.43 misses by $0.25.cash and cash equivalents of $23.2M.Press ReleaseMore news on: Anchiano Therapeutics Ltd, Earnings news and commentary, Healthcare stocks news, ,